BOSTON - Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company, has initiated a rolling submission for a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of avutometinib and defactinib. This combination therapy is aimed at treating adult patients with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) who have previously undergone at least one systemic therapy.
The company has begun submitting sections of the NDA, starting with nonclinical and quality modules. The FDA has agreed to review the primary efficacy analysis from the RAMP 201 study, which includes 12 months of follow-up data. Verastem is planning to complete the clinical module of the NDA in the second half of 2024. If additional data shows substantial improvement over existing therapies for the KRAS wild-type population, the indication for the final submission may be expanded.
Verastem's treatment combination has previously received Breakthrough Therapy Designation and Orphan Drug Designation for certain LGSOC indications, highlighting the absence of FDA-approved treatments for this recurrent cancer. The ongoing RAMP 201 trial has shown promising response rates and durability with low discontinuation due to adverse events.
The company also announced plans to present mature RAMP 201 trial data at a medical conference later in 2024. Additionally, Verastem is conducting an international Phase 3 trial, RAMP 301, to compare the efficacy of the avutometinib and defactinib combination with standard chemotherapy or hormonal therapy for patients with recurrent LGSOC.
Today, Verastem will host an investor conference call and webcast at 8:00 am EDT to discuss the NDA submission and provide an update on the RAMP 201 trial.
LGSOC is a rare and fatal form of ovarian cancer that affects younger women and has a high recurrence rate. The current standard treatments have limited efficacy, with overall response rates between 6-13% and significant discontinuation rates due to adverse events.
InvestingPro Insights
As Verastem Oncology (NASDAQ:VSTM) forges ahead with its NDA submission for a groundbreaking ovarian cancer treatment, the company's financial health and market performance provide critical context for investors. With a market capitalization of $308.25 million, Verastem's valuation reflects investor anticipation surrounding its innovative therapies. However, the company's Price to Earnings (P/E) ratio stands at -2.72, and adjusting for the last twelve months as of Q1 2024, it worsens slightly to -2.92, underscoring the company's current lack of profitability.
InvestingPro data also highlights a Price/Book ratio of 12.3 for the same period, indicating a premium market valuation relative to the company's book value. Despite these figures, Verastem's stock has seen a significant rally with a one-year price total return of 129.12%, perhaps due to investor optimism about the potential market for its cancer therapies.
InvestingPro Tips for Verastem Oncology suggest a mixed financial outlook. On the positive side, the company holds more cash than debt, providing a cushion for ongoing research and development activities. Additionally, two analysts have revised their earnings estimates upwards for the upcoming period, hinting at possible positive developments. On the other hand, the company is quickly burning through cash and suffers from weak gross profit margins, which could impact its long-term sustainability. Moreover, analysts do not expect Verastem to be profitable this year, and net income is projected to drop.
For investors seeking a deeper dive into Verastem Oncology's financials and market performance, InvestingPro offers additional insights. With the use of the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to an extended list of 12 InvestingPro Tips that can further inform investment decisions.
These insights into Verastem's financial health and market performance are essential for investors considering the biopharmaceutical company's stock amidst its promising clinical developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.